Search

Your search keyword '"Tovar, Adolfo A."' showing total 117 results
Start Over Author "Tovar, Adolfo A."
117 results on '"Tovar, Adolfo A."'

4. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic Leukemia

Author

Cruz-Miranda, Gabriela Marisol, primary, Olarte-Carrillo, Irma, additional, Bárcenas-López, Diego Alberto, additional, Martínez-Tovar, Adolfo, additional, Ramírez-Bello, Julian, additional, Ramos-Peñafiel, Christian Omar, additional, García-Laguna, Anel Irais, additional, Cerón-Maldonado, Rafael, additional, May-Hau, Didier, additional, and Jiménez-Morales, Silvia, additional

Published
2024
Full Text
View/download PDF

6. Effect of a Cross-Training and Resistance Exercise Routine on IL-15 in Adults with Type B Acute Lymphoblastic Leukemia during the Induction Phase: Randomized Pilot Study.

Author

Gallardo Rodríguez, Adán Germán, Olarte Carrillo, Irma, Martínez Tovar, Adolfo, Cerón Maldonado, Rafael, Martínez Moreno, Emmanuel, and Ramos Peñafiel, Christian Omar

Subjects
RESISTANCE training, LYMPHOBLASTIC leukemia, ISOMETRIC exercise, ACUTE leukemia, EXERCISE therapy, HEMATOLOGIC malignancies
Abstract

IL-15 is a proinflammatory myokine essential for activating NK cells and CD8+ T lymphocytes, and its overexpression has been related to reducing overall survivorship in patients with acute lymphoblastic leukemia (ALL). Physical exercise has been shown to be safe, feasible, and beneficial in hematological cancers. Exercise requires the activation of muscles that secrete cytokines, such as IL-15, causing immune mobilization. The objective was to compare the outcomes of two training routines on IL-15 and survival prognosis in adult patients diagnosed with ALL. A blind randomized clinical study was carried out where twenty-three peripheral blood samples were obtained pre and postexercise intervention from patients categorized into three types of intervention: the resistance exercise group (REG), the cross-training exercise group (CEG), and the control group (CG). Changes in IL-15 levels during the intervention were not significant in any of the groups (CG p = 0.237, REG p = 0.866, and CEG p = 0.678). However, 87.5% of patients who received an exercise intervention achieved remission, while only 21.73% experienced a relapse. There were no deaths during the study. Although IL-15 level adaptation in the REG and the CG performed similarly, the REG induced a better clinical outcome. Resistance exercises may help improve survival prognosis and reduce relapses in patients with ALL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Efficacy of Bortezomib Combined with Hyper-CVAD in Adults with Relapsed Acute Lymphoblastic Leukemia or Positive Measurable Residual Disease

Author

Ramos Peñafiel, Christian Omar, primary, Pérez Sámano, Daniela, additional, Gallardo-Rodríguez, Adán Germán, additional, Olarte Carrillo, Irma, additional, Terreros Palacios, Camila, additional, Martínez Murillo, Carlos, additional, Barranco Lampón, Gilberto Israel, additional, Cabrera García, Álvaro, additional, Castellanos Sinco, Humberto Baldemar, additional, and Martínez Tovar, Adolfo, additional

Published
2023
Full Text
View/download PDF

10. Opciones para el tratamiento de la recaída en leucemia linfoblástica aguda. Revisión de tema.

Author

Omar Ramos-Peñafiel, Christian, Martínez-Murillo, Carlos, Pérez-Sámano, Daniela, Terreros-Palacios, Camila, Germán Gallardo-Rodríguez, Adán, Olarte-Carrillo, Irma, and Martínez-Tovar, Adolfo

Subjects
LYMPHOBLASTIC leukemia, CHILDHOOD cancer, ACUTE leukemia, COMBINATION drug therapy, YOUNG adults
Abstract

Copyright of Médicas UIS is the property of Universidad Industrial de Santander and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

11. Impacto de la pandemia por SARS-CoV2 en el tratamiento de la leucemia linfoblástica en adultos: experiencia de dos centros de referencia en la Ciudad de México

Author

Ramos-Peñafiel, Christian Omar, primary, Pérez-Sámano, Daniela, additional, Olarte-Carrillo, Irma, additional, Gallardo-Rodríguez, Adán Germán, additional, Cordero-Hernández, Edgar Laurencio, additional, Martínez-Murillo, Carlos, additional, Barranco-Lampón, Gilberto Israel, additional, and Martinez-Tovar, Adolfo, additional

Published
2023
Full Text
View/download PDF

12. Obesidad y riesgo de recaídas en pacientes con Leucemia Linfoblástica Aguda: Estudio retrospectivo

Author

Ramos-Peñafiel, Christian Omar, primary, Bejarano-Rosales, Mónica Patricia, additional, Gallardo-Rodríguez, Adán Germán, additional, Pérez-Sámano, Daniela, additional, Leyton-Rivera, Hugo Roberto, additional, Olarte-Carrillo, Irma, additional, Martínez-Tovar, Adolfo, additional, Tarlovsky, Vanessa Fuchs, additional, Barranco-Lampón, Gilberto, additional, and Alvarez-Altamirano, Karolina, additional

Published
2023
Full Text
View/download PDF

14. Usefulness of the neutrophil-to-lymphocyte, monocyte-to-lymphocyte and lymphocyte-to-platelet ratios for the prognosis of COVID-19-associated complications

Author

Ramos-Peñafiel, Christian, primary, Santos-González, Brenda, additional, Flores-López, Eder N., additional, Galván-Flores, Francisco, additional, Hernández-Vázquez, Lucía, additional, Santoyo-Sánchez, Adrián, additional, Montes de Oca-Yemha, Rosaura, additional, Bejarano-Rosales, Mónica, additional, Rosas-González, Órika, additional, Olarte-Carrillo, Irma, additional, Martínez-Murillo, Carlos, additional, and Martínez-Tovar, Adolfo, additional

Published
2023
Full Text
View/download PDF

17. Frequency and clinical association of NY-ESO-1 gene expression in diffuse large B-cell lymphoma

Author

Olarte-Carrillo, Irma, primary, Ramos-Peñafiel, Christian O., additional, Cerón-Maldonado, Rafael, additional, Barranco-Lampon, Gilberto I., additional, Mendoza-Salas, Iveth, additional, García-Laguna, Anel I., additional, De la Cruz-Rosas, Adrian, additional, Martínez-Murillo, Carlos, additional, Centeno-Cruz, Federico, additional, and Martínez-Tovar, Adolfo, additional

Published
2022
Full Text
View/download PDF

19. Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Author

Mencia Trinchant, Nuria, primary, Kohlschmidt, Jessica, additional, Gomez-Arteaga, Alexandra, additional, Byrd, John C., additional, Stock, Wendy, additional, Mrózek, Krzysztof, additional, Carroll, Andrew J., additional, Stone, Richard M., additional, Pacheco, Eileen, additional, Martinez Tovar, Adolfo, additional, Olarte Carrillo, Irma, additional, Garcia Laguna, Anel, additional, Ramos Peñafiel, Christian, additional, Hassane, Duane C, additional, Eisfeld, Ann-Kathrin, additional, and Guzman, Monica L., additional

Published
2022
Full Text
View/download PDF

20. Gaceta Mexicana de Oncolog�a

Author

Ramos-Peñafiel, Christian O., primary, Rosas-González, Erika A., additional, Olarte-Carrillo, Irma, additional, Bejarano-Rosales, Mónica P., additional, Álvarez-Altamirano, Karolina, additional, Fuchs-Tarlovsky, Vanessa, additional, Martínez-Murillo, Carlos, additional, Santoyo-Sánchez, Adrián, additional, and Martínez-Tovar, Adolfo, additional

Published
2022
Full Text
View/download PDF

25. Association Analysis Between the Functional Single Nucleotide Variants in miR-146a, miR-196a-2, miR-499a, and miR-612 With Acute Lymphoblastic Leukemia

Author

Jiménez-Morales, Silvia, primary, Núñez-Enríquez, Juan Carlos, additional, Cruz-Islas, Jazmín, additional, Bekker-Méndez, Vilma Carolina, additional, Jiménez-Hernández, Elva, additional, Medina-Sanson, Aurora, additional, Olarte-Carrillo, Irma, additional, Martínez-Tovar, Adolfo, additional, Flores-Lujano, Janet, additional, Ramírez-Bello, Julian, additional, Pérez-Saldívar, María Luisa, additional, Martín-Trejo, Jorge Alfonso, additional, Pérez-Lorenzana, Héctor, additional, Amador-Sánchez, Raquel, additional, Mora-Ríos, Felix Gustavo, additional, Peñaloza-González, José Gabriel, additional, Duarte-Rodríguez, David Aldebarán, additional, Torres-Nava, José Refugio, additional, Flores-Bautista, Juan Eduardo, additional, Espinosa-Elizondo, Rosa Martha, additional, Román-Zepeda, Pedro Francisco, additional, Flores-Villegas, Luz Victoria, additional, Tamez-Gómez, Edna Liliana, additional, López-García, Víctor Hugo, additional, Lara-Ramos, José Ramón, additional, González-Ulivarri, Juana Esther, additional, Martínez-Silva, Sofía Irene, additional, Espinoza-Anrubio, Gilberto, additional, Almeida-Hernández, Carolina, additional, Ramírez-Colorado, Rosario, additional, Hernández-Mora, Luis, additional, García-López, Luis Ramiro, additional, Cruz-Ojeda, Gabriela Adriana, additional, Godoy-Esquivel, Arturo Emilio, additional, Contreras-Hernández, Iris, additional, Medina-Hernández, Abraham, additional, López-Caballero, María Guadalupe, additional, Hernández-Pineda, Norma Angélica, additional, Granados-Kraulles, Jorge, additional, Rodríguez-Vázquez, María Adriana, additional, Torres-Valle, Delfino, additional, Cortés-Reyes, Carlos, additional, Medrano-López, Francisco, additional, Pérez-Gómez, Jessica Arleet, additional, Martínez-Ríos, Annel, additional, Aguilar-De-los-Santos, Antonio, additional, Serafin-Díaz, Berenice, additional, Gutiérrez-Rivera, María de Lourdes, additional, Merino-Pasaye, Laura Elizabeth, additional, Vargas-Alarcón, Gilberto, additional, Mata-Rocha, Minerva, additional, Sepúlveda-Robles, Omar Alejandro, additional, Rosas-Vargas, Haydeé, additional, Hidalgo-Miranda, Alfredo, additional, and Mejía-Aranguré, Juan Manuel, additional

Published
2021
Full Text
View/download PDF

26. Blood type does not modify prognosis in patients with COVID-19: experience in a COVID-19 hospital in Mexico

Author

Ramos-Peñafiel, Christian, primary, Mader-Maldonado, Elizabeth, additional, Martínez-Murillo, Carlos, additional, Olarte-Carrillo, Irma, additional, Balderas-Delgado, Carolina, additional, Cabrera-García, Álvaro, additional, Valencia-Rocha, Ubaldo, additional, Bermeo-Maldonado, Emmanuel, additional, Santoyo-Sánchez, Adrián, additional, and Martínez-Tovar, Adolfo, additional

Published
2021
Full Text
View/download PDF

28. Impact of the ABCB1 Drug Resistance Gene on the Risk Factors of Patients with COVID-19 and Its Relationship with the Drugs Used.

Author

Carrillo, Irma Olarte, Peñafiel, Christian Omar Ramos, Salas, Iveth Mendoza, Maldonado, Rafael Cerón, Laguna, Anel Irais García, De la Cruz Rosas, Adrián, Murrillo, Carlos Martinez, and Tovar, Adolfo Martinez

Subjects
COVID-19, SARS-CoV-2, DISEASE risk factors, CORONAVIRUS disease treatment, MIDDLE East respiratory syndrome, DRUG resistance
Abstract

Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19. Keywords: ABCB1; SARS-CoV2; drug transporter genes EN ABCB1 SARS-CoV2 drug transporter genes 2661 2669 9 06/09/22 20220501 NES 220501 Background The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus that causes the disease by Coronavirus 2019 (COVID-19).[1] SARS-CoV-2 was reported for the first time in the Chinese city of Wuhan and has spread rapidly around the world through human interactions. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. [Extracted from the article]

Published
2022
Full Text
View/download PDF

29. Utilidad de los índices neutrófilo/linfocito, monocito/linfocito y linfocito/plaqueta para el pronóstico de complicaciones asociadas a COVID-19

Author

Ramos-Peñafiel, Christian O., primary, Santos-González, Brenda, additional, Flores-López, Eder N., additional, Galván-Flores, Francisco, additional, Hernández-Vázquez, Lucía, additional, Santoyo-Sánchez, Adrián, additional, Montes de Oca-Yemha, Rosaura, additional, Bejarano-Rosales, Mónica, additional, Rosas-González, Érika, additional, Olarte-Carrillo, Irma, additional, Martínez-Murillo, Carlos, additional, and Martínez-Tovar, Adolfo, additional

Published
2020
Full Text
View/download PDF

30. Abstract C061: Molecular landscape of acute myeloid leukemia in Mexico

Author

Gomez-Arteaga, Alexandra, primary, Mencia-Trinchant, Nuria, additional, Tovar, Adolfo Martinez, additional, Carrillo, Irma Olarte, additional, Laguna, Anel Garcia, additional, Fuller, Etta Rozen, additional, Penafiel, Christian Ramos, additional, Guzman, Monica L., additional, and Hassane, Duane C., additional

Published
2020
Full Text
View/download PDF

33. Usefulness of two clinical (CBC and PETHEMA) scores for predicting early death in patients with acute promyelocytic leukemia: A single-center study in Mexico City

Author

Ramos-Peñafiel, Christian O., primary, Montaño-Figueroa, Efreen, additional, Castellanos-Sinco, Humberto, additional, Olarte-Carrillo, Irma, additional, Santoyo-Sánchez, Adrián, additional, Rozen-Fuller, Etta, additional, Barranco-Lampon, Gilberto, additional, Zazueta-Pozos, Juan F., additional, and Martínez-Tovar, Adolfo, additional

Published
2019
Full Text
View/download PDF

34. Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City

Author

Olarte-Carrillo, Irma, primary, Garcia Laguna, Anel, additional, Ramos Peñafiel, Christian Omar, additional, Arratia Gutierrez, Brenda, additional, Centeno Cruz, Federico, additional, Paredes Sanchez, Jhoana, additional, Rozen Fuller, Etta, additional, Kassack Ipiña, Juan Julio, additional, Collazo Jaloma, Juan, additional, and Martinez Tovar, Adolfo, additional

Published
2019
Full Text
View/download PDF

35. Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia

Author

Ramos Peñafiel, Christian, Olarte Carrillo, Irma, Ceron Maldonado, Rafael, Miranda Peralta, Enrique, Rozen Fuller, Etta, Kassack Ipiña, Juan Julio, Centeno Cruz, Federico, Collazo Jaloma, Juan, and Martínez Tovar, Adolfo

Subjects
endocrine system diseases, Therapeutics, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Metformin
Abstract

Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and Methods. We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.

Published
2018

36. Analysis of the dynamic aberrant landscape of DNA methylation and gene expression during arsenic-induced cell transformation

Author

Barajas-Olmos, Francisco M., primary, Ortiz-Sánchez, Elizabeth, additional, Imaz-Rosshandler, Ivan, additional, Córdova-Alarcón, Emilio J., additional, Martínez-Tovar, Adolfo, additional, Villanueva-Toledo, Jairo, additional, Morales-Marín, Mirna E., additional, Cruz-Colín, José L., additional, Rangel, Claudia, additional, Orozco, Lorena, additional, and Centeno, Federico, additional

Published
2019
Full Text
View/download PDF

38. Factores pronósticos de remisión en pacientes con leucemia linfoblástica aguda posterior a primer recaída

Author

Ramos-Penafiel, Christian Omar, Olarte-Carrillo, Irma, Santoyo-Sánchez, Adrián, Castellanos-Sinco, Humberto, Montano-Figueroa, Efreen, León-González, Guadalupe, Cabrera-Ozuna, Silvia, Collazo-Jaloma, Juan, and Martínez-Tovar, Adolfo

Subjects
Supervivencia, Leucemia-linfoma, linfoblástico de células precursoras, Survival, Risk Factors, Remission Induction, Inducción de remisión, Precursor Cell Lymphoblastic Leukaemia-Lymphoma, Anti-neoplastic Combined Chemotherapy Protocols, Protocolos de quimioterapia, combinada antineoplásica, Factores de riesgo
Abstract

Objetivos: Identificar aquellos factores que impactan en la respuesta terapéutica para alcanzar una segunda remisión (2 RC) en pacientes con leucemia aguda linfobl´stica (LAL) en recaída. Métodos: Estudio observacional y analítico anidado en una cohorte retrospectiva de adultos (>18 años) portadores de LAL que fueron atendidos durante 2008-2014 y que interrumpieron el protocolo HGMLAL07 al detectarse recaída e iniciaron otro esquema. Resultados: Se estudiaron 69 pacientes y el 62,3% (n = 43) correspondía a hombres. La media de edad fue de 29 años. Los regímenes terapéuticos empleados fueron: alta intensidad (55,1%) [Hyper-CVAD (n = 34), IDA-Flag (n = 1), mitoxantrona-DARAC (n = 3) ], moderada intensidad (4,3%) [Esquemas de reinducción (n = 3) ] y tratamiento paliativo de baja intensidad con soporte transfusional (40,6%, n = 28). Solo 19 pacientes (27,5%) integraron una 2 RC. La media de supervivencia fue 120 (2- 575) días y el 29% sobrevivió al año de seguimiento. El uso de un segundo régimen intensivo o moderado no brindó ventaja sobre el esquema conservador (prueba log-Rank, p = 0,812). Ninguna variable demostró valor pronóstico sobre la supervivencia a 1 año. La duración de la primera RC (OR 6,78, p = 0,005, 95% IC: 1,7532-26,2803) y recibir un primer tratamiento intensivo (OR 0,22, p = 0,018, 95% IC: 0,0661-0,7813) fueron variables pronósticas de falla terapéutica para alcanzar la 2 RC. Conclusiones: Poseer una primera RC < 1 año fue un factor de riesgo importante para no integrar una 2 RC. No se identificaron factores pronósticos de supervivencia ni superioridad de alguno de los esquemas de rescate empleados. Aims: To identify those factors that affect therapeutic response to achieve a second remission (2 RC) in patients with acute lymphoblastic leukaemia (ALL) in relapse. Methods: Observational, descriptive and analytical study nested in a retrospective cohort of adults (> 18 years-old) ALL carriers treated during the period from 2008 to 2014 that disrupted the HGMLAL07 protocol when relapse was detected and began another therapeutic scheme. Results: The study included 69 patients, of whom 62.3% (n = 43) were males, and the mean age was 29 years-old. The therapeutic regimens used were: high intensity (55.1%) [Hyper-CVAD (n = 34), IDA-Flag (n = 1), mitoxantrone-DARAC (n = 3) ], moderate intensity (4.3%) [Re-induction schemes (n = 3) ], and palliative treatment of low intensity with transfusion support (40.6%, n = 28).Only 19 patients (27.5%) achieved a 2 RC. The median overall survival was 120 (2-575) days, 29% of patients were alive at one year. Using a high or moderate intensity regime as the rescue scheme gave no advantage over the conservative one (log-rank test, P = .812). None of the variables showed prognostic value of survival at one year. The duration of the first RC (OR 6.78, P = .005, 95% CI; 1.75 -26.28) and receiving high intensity treatment (OR 0.22, P = 018, 95% CI: 0.06 -0.78) were predictors of treatment failure to achieve 2 RC. Conclusions: To achieve a first RC < 1 year was an important risk factor for not achieving a 2 RC. No prognostic factors for survival were identified. None of the schemes used for rescue showed superiority.

Published
2016

40. Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia

Author

Ramos Peñafiel, Christian, primary, Olarte Carrillo, Irma, additional, Ceron Maldonado, Rafael, additional, Miranda Peralta, Enrique, additional, Rozen Fuller, Etta, additional, Kassack Ipiña, Juan Julio, additional, Centeno Cruz, Federico, additional, Collazo Jaloma, Juan, additional, and Martínez Tovar, Adolfo, additional

Published
2018
Full Text
View/download PDF

43. Effect of the Adition of Metformin on the expressión of Multidrug-Resistance Genes (ABCB1, ABCG2) in Acute Lymphoblastic Leukemia: In Vitro and In Vivo Study

Author

Ramos Peñafiel, Christian Omar, primary, Olarte Carrillo, Irma, additional, Cerón Maldonado, Rafael, additional, Santoyo Sánchez, Adrián, additional, Castellanos Sinco, Humberto Baldemar, additional, Montaño Figueroa, Efreen, additional, Queipo García, Gloria, additional, and Martínez Tovar, Adolfo, additional

Published
2016
Full Text
View/download PDF

44. Efecto de la adición de metformina a un pretratamiento con esteroides en pacientes adultos con leucemia linfoblástica aguda y en la viabilidad de la línea celular MOLT-4

Author

Ramos Peñafiel, Christian Omar, Olarte Carrillo, Irma, Martínez Tovar, Adolfo, Castellanos Sinco, Humberto, Zamora Domínguez, Jorge, Santoyo Sánchez, Adrián, Rozen Fuller, Etta, Miranda Peralta, Enrique, and Collazo Jaloma, Juan

Subjects
Esteroides, Steroids, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Metformina, Leucemia-Linfoma Linfoblástico de Células Precursoras, Metformin
Abstract

Introducción: metformina es un medicamento antidiabético evaluado en varios modelos in vitro e in vivo de cáncer ya que es capaz de incrementar la proteincinasa activada por adenosin monofosfato y bloquear las vías de señalización tumoral. Objetivo: evaluar los efectos antitumorales de metformina en línea celular MOLT-4 en pacientes bajo tratamiento de inducción a la remisión. Materiales y métodos: fase in vitro: ensayo en línea celular MOLT-4 adicionando metformina 40 mM evaluando la viabilidad y ciclo celular mediante citometría de flujo. Fase clínica: Estudio de casos y controles en pacientes portadores de leucemia linfoblástica aguda de novo, adicionando metformina 850 mg cada ocho horas en etapa de pretratamiento e inducción a la remisión, contra el registro histórico del protocolo institucional HGMLAL07. Para el análisis estadístico se utilizó el test de chi-cuadrado, estudio multivariado para factores de riesgo y evaluación del efecto sobre la remisión mediante Odds Ratio. Resultados: ensayo celular: meformina inhibió la viabilidad celular a las 120 horas, reduciendo el porcentaje de células en fase S. Estudio clínico: en un total de 151 pacientes, el 29,1% correspondieron al brazo de metformina. La mayor tasa de respuesta favorable a esteroides como de remisiones completas se encontraron en los pacientes que recibieron metformina (59,1% versus 26,2% y 81,8% versus 57,9%) con significancia estadística (p= 0.000* y 0,006 95% IC). Conclusiones: la adición de metformina a la quimioterapia incremento la respuesta favorable a esteroides y las tasas de remisiones completas. In vitro, y semejante a otros modelos, metformina arresta a las células en G0/G1, induciendo una disminución en la viabilidad celular. MÉD.UIS. 2015;28(2):221-8 Introduction: metformin, antidiabetic drug evaluated in several in vitro and in vivo cancer models, is able of increasing the adenosine monophosphate activated protein kinase and block tumor signaling pathways. Objetive: to evaluate the antitumor effects of metformin in MOLT-4 cell line and in patients under treatment for remission induction. Materials and methods: in vitro phase: essay in MOLT-4 cell line adding metformin 40 mM evaluating the viability and cell cycle by flow cytometry. Clinic phase: Case-control study in patients with de novo acute lymphoblastic leukemia, adding metformin three time a day on pretreatment stage and remission induction, against the historical record of the institutional protocol HGMLAL07. Statistical analysis: chi-square analysis, multivariate analysis for risk factors and evaluation of the effect over the remission by Odds ratio. Results: celular assay: metformina inhibited cell viability at 120 hours reducing the percentage of cells in phase S. Clinical assay: 151 patients were studied, 29.1% on metformina arm. The highest rate of good steroid response and complete remissions were found in patients who received metformin (59,1% versus 26,2% and 81,8% vs 57,9%) statistically significant (p= 0.000* and 0.006, 95% IC). Conclusions: the addition of metformin to chemotherapy increased the good steroids response to steroids and rates of complete remissions. In vitro, and similar to other models, metformin arrest cells in G0/G1, inducing a decrease in cell viability. MÉD.UIS. 2015;28(5):221-8

Published
2015

45. Factores pronósticos de remisión en pacientes con leucemia linfoblástica aguda posterior a primer recaída

Author

Ramos-Peñafiel, Christian Omar, primary, Olarte-Carrillo, Irma, additional, Santoyo-Sánchez, Adrián, additional, Castellanos-Sinco, Humberto, additional, Montaño-Figueroa, Efreen, additional, León-González, Guadalupe, additional, Cabrera-Ozuna, Silvia, additional, Collazo-Jaloma, Juan, additional, and Martínez-Tovar, Adolfo, additional

Published
2016
Full Text
View/download PDF

47. The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women

Author

Gutierrez-Malacatt, Humberto, primary, Ayala-Sanchez, Manuel, additional, Aquino-Ortega, Xochitl, additional, Dominguez-Rodriguez, Jacqueline, additional, Martinez-Tovar, Adolfo, additional, Olarte-Carrillo, Irma, additional, Martinez-Hernandez, Angelica, additional, Cecilia, Contreras-Cubas C, additional, Orozco, Lorena, additional, and Cordova, Emilio J, additional

Published
2016
Full Text
View/download PDF

48. Comparación del hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México

Author

Ramos-Peñafiel, Christian Omar, primary, Cabrera-García, Álvaro, additional, Rozen-Fuller, Etta, additional, González-León, Guadalupe, additional, Balderas, Carolina, additional, Kassack-Ipiña, Juan Julio, additional, Castellanos-Sinco, Humberto, additional, Martínez-Murillo, Carlos, additional, Montaño-Figueroa, Efreen, additional, Martínez-Tovar, Adolfo, additional, Olarte-Carrillo, Irma, additional, Santoyo-Sánchez, Adrián, additional, and Collazo-Jaloma, Juan, additional

Published
2014
Full Text
View/download PDF

49. Effects Of Metformin Addition To a Standard Chemotherapy Regimen For The Treatment Of Adult Acute Lymphoblastic Leukemia. An In Vitro and In Vivo study

Author

Ramos Peñafiel, Christian Omar, primary, Carrillo, Irma Olarte, additional, Domínguez, Jorge Zamora, additional, Castellanos Sinco, Humberto Baldemar, additional, Fuller, Etta Rozen, additional, Peralta, Enrique Miranda, additional, Jaloma, Juan Collazo, additional, and Tovar, Adolfo Martínez, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results